Why the study?
Are different low-molecular-weight heparins (dalteparin, enoxaparin, tinzaparin) similar in efficacy and safety for preventing and treating venous thromboembolism in surgical patients?
Are different low-molecular-weight heparins (dalteparin, enoxaparin, tinzaparin) similar in efficacy and safety for preventing and treating venous thromboembolism in surgical patients?
Answers are grounded in this paper and cite their sources.
Different low-molecular-weight heparins (dalteparin, enoxaparin, tinzaparin) can be considered clinically equivalent for VTE prophylaxis and treatment in surgical patients.
The pharmacodynamic properties of low-molecular-weight heparins differ. Data from randomized clinical trials show that despite these differences, the agents have similar efficacy and safety profiles in preventing and treating new and recurrent venous thromboembolism in patients who underwent general surgery or total hip or knee replacement. Dalteparin, enoxaparin, or tinzaparin, when administered at the dosages used in the reviewed clinical trials, are essentially indistinguishable.
No takes yet. Share an insight, caveat, or question.
Larry M. Lopez (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: